Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
26.89
+0.02 (0.07%)
May 26, 2026, 2:02 PM EDT - Market open
Genmab Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Genmab stock has a consensus rating of "Strong Buy" and an average price target of $37.55. The average 1-year stock price forecast is 39.64% higher than the current stock price, while the lowest is $32 (+19.00%) and the highest is $48 (+78.51%).
Price Target: $37.55 (+39.64%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Genmab stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 8 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 19, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $40 | Buy | Maintains | $40 | +48.75% | May 9, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $32 | Hold | Maintains | $32 | +19.00% | May 8, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $34 → $33 | Hold | Maintains | $34 → $33 | +22.72% | May 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $40 → $38 | Buy | Reiterates | $40 → $38 | +41.32% | Apr 30, 2026 |
Financial Forecast
Revenue This Year
4.39B
from 3.72B
Increased by 17.90%
Revenue Next Year
5.09B
from 4.39B
Increased by 16.05%
EPS This Year
11.98
from 15.37
Decreased by -22.03%
EPS Next Year
17.03
from 11.98
Increased by 42.07%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.7B | 5.6B | ||||||
| Avg | 4.4B | 5.1B | ||||||
| Low | 3.6B | 4.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.4% | 27.5% | ||||||
| Avg | 17.9% | 16.1% | ||||||
| Low | -2.5% | -4.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 19.02 | 22.92 | ||||||
| Avg | 11.98 | 17.03 | ||||||
| Low | 9.61 | 11.51 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 23.7% | 91.3% | ||||||
| Avg | -22.0% | 42.1% | ||||||
| Low | -37.5% | -4.0% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.